Definitive Contract 75A50120C00179

Award Date 9/23/20
Potential Completion Date 7/30/21
Potential Value $684K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Austin, TX 78727, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a firm fixed-price purchase order contract worth $5,389,813.00 to Luminex Corporation. The contract is for the integration of the SARS-CoV-2 virus with the NxTAG Respiratory Pathogen Panel and the submission of a 510(k) application to the U.S. Food and Drug Administration. Luminex is a manufacturer of biological testing technologies, including multiplex diagnostic solutions,...
This is a $9,850,000.00 firm fixed price purchase order awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Luminex Corporation. The contract is to expand the use of Luminex's ARIES SARS-CoV-2 assay, which is a molecular diagnostic test for COVID-19. This award was not set aside for any specific business type. Luminex is a manufacturer of biological testing technologies, including multiplex diagnostic solutions,...
Luminex Corporation was awarded a $642,450 firm fixed price definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop an extended panel for the Luminex NXTAG COVID-19 diagnostic test. The contract is being performed in Austin, Texas over a period of four months ending July 1, 2020. This award was made under Special Instructions 019 of the department's Easy Broad Agency Announcement BAA-20-100-SOL-0002, which...
This federal contract award is for an XMAP SARS-COV-2 Multi-Antigen IgG Assay, with a ceiling value of $96,587.93, awarded to Luminex Corp by the Centers for Disease Control and Prevention (CDC) on May 7, 2021. The contract is a firm fixed-price purchase order with a completion date of July 9, 2021. Luminex Corp is the prime contractor and no set-aside was used. This award is associated with the CDC's efforts to respond to the Coronavirus COVID-19 public health emergency. Luminex Corp is a...
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded Luminex Corporation a $1.2 million firm-fixed price purchase order to complete the final stages of obtaining FDA 510(k) clearance for its proprietary ARIES Flu A/B/RSV + SARS-CoV-2 diagnostic test. Luminex will perform necessary clinical evaluations and submit the 510(k) application to achieve long-term FDA clearance of the ARIES test, which the agency considers critical to its...
This $55,458.60 firm fixed price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Luminex Corporation, a manufacturer of biological testing technologies, to provide laboratory supplies. The contract does not have a set-aside designation. Luminex has previously received prime and subcontract awards from various federal agencies, including the Department of Veterans Affairs, Department of Defense, and National Institutes of Health, to deliver immunology...
Luminex Corporation was awarded a $132,000 firm fixed price contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4 to provide COVID-19 testing supplies and equipment. The contract was awarded under the Multiple Award Schedule contracting vehicle to support the agency's response to the coronavirus pandemic. No set-aside provisions were applied to this award for COVID-19 related products and services. Performance will occur in...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $241,355.50 firm fixed price purchase order to Luminex Corporation, a foreign-owned for-profit manufacturer of biological testing technologies. The contract is for the provision of lab supplies, with no set-aside designation, and a completion date of October 1, 2021. Luminex is a provider of proprietary multiplex diagnostic solutions to federal agencies, including the CDC, Department of Veterans...
This is a $36,972.00 delivery order contract awarded by the Defense Logistics Agency's Medical Supply Chain division to Luminex Corp, a foreign-owned, for-profit manufacturer of biomedical diagnostic technologies based in Austin, Texas. The contract is for the delivery of NXTAG Respiratory Pathogen Panels (RPP) and has a completion date of February 5, 2025. The contract is a firm fixed-price award without any small business set-aside designations. Luminex holds several significant federal...
Luminex Corporation was awarded a $55,415.62 delivery order against its Multiple Award Schedule contract with the General Services Administration to provide an ARIES Two Module System for molecular testing of the Coronavirus Disease 2019 (COVID-19) to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4 located in Pittsburgh, Pennsylvania. The firm fixed price order has a completion date of September 30, 2020 and was awarded on March 19, 2020 to...

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $683,500 firm fixed price definitive contract to Luminex Corporation of Austin, Texas. The contract is for the delivery of Luminex's XMAP SARS-CoV-2 Multi-Antigen Antibody Typing Assay to support the agency's coronavirus COVID-19 response efforts. No set aside designation or major subcontractors were indicated. Luminex will provide its assay from September 2020 through July 2021 to support HHS' goal of monitoring the spread and prevalence of SARS-CoV-2 antibodies in impacted populations as part of the overall national response to the COVID-19 pandemic.

Generated 12/25/23, 5:17 AM